ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer Research (AACR) 2021 Annual M...
09 Aprile 2021 - 07:38AM
ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming
American Association for Cancer Research (AACR) 2021 Annual Meeting
- Oral presentation of Phase 1 dose escalation study of
TB-403 in pediatric subjects with relapsed or refractory
medulloblastoma (MB)
- Poster presentation of research findings of best
therapeutic approach to target CCR8 expressed on tumor regulatory T
cells to boost anti-tumor immune responses
Leuven, Belgium 9th April 2021 – 7.30 AM
CET – ONCURIOUS NV, a Belgium-based biotech company
focused on developing innovative oncology treatments, today
announces that it will make two presentations at the upcoming AACR
Virtual Annual Meeting 2021 which will take place from 9 to 14
April.
The first of these is an oral
presentation of data from a Phase 1 dose escalation study
of TB-403, a humanized monoclonal antibody against placental growth
factor (PlGF), in pediatric cancer subjects for treatment of
medulloblastoma:
Title: A Phase 1, open label, multicenter,
dose escalation study of TB-403 in pediatric subjects with relapsed
or refractory medulloblastoma, neuroblastoma, Ewing Sarcoma or
alveolar rhabdomyosarcoma
Presented by: Dr. Giselle Sholler, Director at
the Isabella Santos Foundation Solid and Rare Tumor Program, Chair
at Beat Childhood Cancer Research Consortium, and Professor,
Pediatric Oncology at the Levine Children’s Hospital in Charlotte,
NC.
Presentation #: CT015
Session Title: Early Clinical Trials with New
Anticancer Agents
Session Date and Time: Saturday 10th April from
1:30 PM to 3:30 PM US EDT
The second presentation is an e-poster
presentation of preclinical data:
Title: Investigation of the best
therapeutic approach to target CCR8 expressed on tumor regulatory T
cells to boost anti-tumor immune responses
Authors: Heleen Roose, Elizabeth Allen,
Helena Van Damme, Bruno Dombrecht, Rosa Martín-Pérez, Damya Laoui,
Jo A. Van Ginderachter, Pascal Merchiers. Oncurious NV, Leuven,
Belgium, Laboratory of Cellular and Molecular Immunology, Vrije
Universiteit Brussel and Myeloid Cell Immunology Lab, VIB Center
for Inflammation Research, Brussels, Belgium, VIB Discovery
Sciences, Leuven-Ghent, Belgium.
Date and Time: The e-poster will be available on
AACR’s website on Saturday 10th April at 8:30 AM US EDT (the first
day of the virtual AACR Annual Meeting). The e-poster will remain
available for viewing through to Monday 21st June 2021.
The abstract can be viewed here.
In February 2021, The Journal for Immunotherapy
of Cancer (a BMJ journal) published a paper on the efficacy and
safety of targeting CCR8 for the depletion of tumor-promoting tumor
infiltrating Tregs in combination with anti-PD-1 therapy. For more
information please see Oncurious press release here.
For further information please
contact:
Oncurious NVWouter Piepers, Investor Relations& Corporate
CommunicationsTel: +32 478 33 56
32wouter.piepers@oncurious.com |
VIBElisabeth StesExternal Relations Manager+32 9 244 66 11 / +32
486 825 902Elisabeth.stes@vib.be |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer HallTel:
+44 20 7638 9571oncurious@citigatedewerogerson.com |
About Oncurious
ONCURIOUS NV is a Belgium-based biotech company
focused on developing innovative oncology treatments derived from a
series of promising new targets that are designed to enhance T cell
activity and migration and infiltration into resistant tumour
sites, boosting the response to immunotherapy in the large numbers
of patients who respond sub-optimally to existing treatment.
Oncurious is working on a series of novel
immuno-modulatory targets offering the potential to overcome tumor
resistance mechanisms, which current immune checkpoint inhibitors
cannot address, and thereby significantly enhancing the responses
to immunotherapy across multiple tumor types. The team has
discovered a potent and diverse panel of leads targeting human CCR8
and is entering the final stage of preclinical candidate
selection.
Oncurious is majority owned by Oxurion NV
(Euronext Brussels: OXUR), a biopharmaceutical company developing
next generation standard ophthalmic therapies designed to better
preserve vision in patients with retinal vascular disorders,
and VIB. Oncurious notes that BioInvent AB contributed to the
initial stages of the trial.
More information: www.oncurious.com
About VIB
VIB is a strategic research center in life
sciences and biotech. The results of VIB’s top research are
actively translated into added value for society. VIB unites the
expertise of 81 research groups thematically organized into 8
research centers. VIB’s technology transfer team proactively
translates new biological findings into new economic activities,
such as starting up new companies and partnerships with the biotech
and pharmaceutical industry. Since its foundation in 1996, VIB has
created 20 start-up companies. VIB also engages actively in the
public debate on biotechnology by developing and disseminating a
wide range of science-based information about all aspects of
biotechnology. VIB has a close partnership with five Flemish
universities – Ghent University, KU Leuven, University of Antwerp,
Vrije Universiteit Brussel and Hasselt University.
More information: www.vib.be
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2023 a Mar 2024